Enbrel® (etanercept)

Enbrel (etanercept) is covered for specified FDA‑approved and select compendial/off‑label immune‑mediated indications — including ankylosing spondylitis, juvenile idiopathic arthritis (including juvenile spondyloarthropathy), plaque psoriasis (adult and pediatric), psoriatic arthritis, rheumatoid arthritis, Behcet’s disease, GVHD, pyoderma gangrenosum, Still’s disease and other spondyloarthritis subtypes — subject to indication‑specific minimum ages and prescriber‑specialty requirements; biosimilars do not count as prior biologic trials for step therapy. Coverage requires documented diagnosis, specialist involvement or consultation, fulfillment of indication‑specific prior therapy/trial and minimum trial‑duration rules (with some exceptions for prior biologic exposure), objective evidence of clinical response at reauthorization, and adherence to specified initial and renewal approval durations.

"Ankylosing spondylitis (AS)"